common variable immunodeficiency
Upload: chulalongkorn-allergy-and-clinical-immunology-research-group
Post on 24-May-2015
2.229 views
DESCRIPTION
Common variable immunodeficiency,Presented by Sasikarn Suesirisawad, MDTRANSCRIPT
![Page 1: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/1.jpg)
COMMON VARIABLE IMMUNODEFICIENCY
Sasikarn Suesirisawad, MD
![Page 2: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/2.jpg)
DEFINITION Presence of hypogammaglobulinemia of two
or more immunoglobulin isotype (low IgG, IgA, or IgM)
Recurrent sinopulmonary infection
Impaired functional antibody responses Absent isohaemagglutinin Poor responses to protein (diphtheria, tetanus) or
polysaccharide vaccines(S. pneumoniae)
Other finding: autoimmunity, granulomatous disease, and neoplasia
![Page 3: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/3.jpg)
![Page 4: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/4.jpg)
![Page 5: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/5.jpg)
![Page 6: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/6.jpg)
![Page 7: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/7.jpg)
FLOW CYTOMETRY B CELL SUBPOPULATION
![Page 8: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/8.jpg)
ASSOCIATION OF CLINICAL PHENOMENA WITH DYSREGULATED B CELL SUBPOPULATIONS
![Page 9: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/9.jpg)
EVALUATION OF THE PARIS AND FREIBURG CLASSIFICATION SCHEME.
P=0.03
P=0.02
P<0.001
P=0.04
P=0.02
![Page 10: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/10.jpg)
P<0.001
P<0.01
P=0.02
![Page 11: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/11.jpg)
P=0.03
P=0.016
P=0.049
P<0.01
P=0.009
![Page 12: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/12.jpg)
T CELL AND CELLULAR ABNORMALITIES
Decreased T lymphocyte proliferation to mitogens and Ag (40 % of patients)
Clin Immunol. 1999;92(1):34.
Low CD4/CD8 T cell ratio due to decrease in CD4 or increase CD8
Reduced T regulatory cells Clin Exp Immunol. 2009;156(3):446. Clin Immunol. 2009;131(2):240.
![Page 13: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/13.jpg)
EPIDEMIOLOGY Usually diagnosed in the second or third
decade of life.
25 % of all CVID pts present in childhood or adolescence, earlier peak of diagnosis at 8 yrs of age.
An Pediatr (Barc). 2011;74(2):74.J Pediatr. 2009;154(6):888.
![Page 14: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/14.jpg)
![Page 15: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/15.jpg)
Median age of first symptom was 19 yr
Median age at CVID diagnosis was 33.9 yr
![Page 16: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/16.jpg)
Delay between first symptom and diagnosis of CVID
![Page 17: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/17.jpg)
![Page 18: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/18.jpg)
![Page 19: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/19.jpg)
![Page 20: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/20.jpg)
![Page 21: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/21.jpg)
73%: RS infection
![Page 22: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/22.jpg)
Coincidence of granulomatous disease and autoimmmune cytopenia with splenomegaly in
CVID
![Page 23: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/23.jpg)
![Page 24: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/24.jpg)
Mary Lucas et al. JACI 2010
![Page 25: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/25.jpg)
![Page 26: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/26.jpg)
![Page 27: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/27.jpg)
PULMONARY MANIFESTATIONS 73 % of CVID develop chronic structural
pulmonary complications: bronchiectasis and bronchial wall thickening
Pediatr Allergy Immunol. 2010;21(5):793.
54 children with CVID, structural lung disease was found in > 85 % of patients
Chest. 2010;138(2):371.
![Page 28: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/28.jpg)
PULMONARY MANIFESTATIONS Obstructive flow-volume curves found in
50 - 94 % of pts. Pediatr Allergy Immunol. 2010;21(5):793.
12 CVID, 83 % asthma, none life-threatening symptoms.
Ann Allergy Asthma Immunol. 2006;97(5):653
Obstructive lung disease in children with CVID appears to be higher than adults.
![Page 29: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/29.jpg)
![Page 30: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/30.jpg)
ALLERGIC DISEASES 38 % of pts in one of cohorts had some
evidence of an allergic disease: food allergy, eczema, urticaria, rhinitis, asthma.
J Pediatr. 2009;154(6):888.
83 % had asthma. Ann Allergy Asthma Immunol.
2006;97(5):653
![Page 31: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/31.jpg)
GASTROINTESTINAL PROBLEMS Diarrhea, malabsorption, wt loss are common
problems in CVID. Clin Immunol. 1999;92(1):34.
GI infections: H. pylori and Giardia lamblia. Salmonella, Shigella, Campylobacter.
Ann Intern Med. 1993;118(9):720
Crohn's disease and ulcerative colitis Clin Immunol. 1999;92(1):34.
Nodular intestinal hyperplasia occurs relatively frequently in adolescents with CVID
Dig Dis Sci. 2007;52(11):2977.
![Page 32: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/32.jpg)
![Page 33: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/33.jpg)
![Page 34: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/34.jpg)
![Page 35: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/35.jpg)
a b
d e
c
f g h
![Page 36: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/36.jpg)
AUTOIMMUNE DISEASE Autoimmunity is seen in 20 - 25 % of
CVID.
Autoimmune cytopenias are more common presenting disorder in children than adults.
Autoimmune neutropenia, thrombocytopenia, hemolytic anemia
DM, psoriasis, SLE, RA, JIA
![Page 37: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/37.jpg)
![Page 38: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/38.jpg)
MALIGNANCY Lifetime risk of malignancy: 1.4 - 7 %
The most frequently diagnosed disorder is B cell lymphoma
Am J Hematol. 2002;69(3):171.
![Page 39: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/39.jpg)
![Page 40: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/40.jpg)
NEURODEGENERATIVE DISEASES OR ENCEPHALOPATHY adults with CVID, enteroviral and JC
virus infection can cause neurodegeneration.
Enteroviral infection has not described in pediatric CVID.
In contrast, neurodegenerative diseases described in other pediatric immunodeficiencies (esp. X-linked agammaglobulinemia)
Ann Allergy Asthma Immunol. 2007;98(5):483Brain. 1996;119 ( Pt 1):1.
![Page 41: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/41.jpg)
TACI
BAFF-R
![Page 42: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/42.jpg)
![Page 43: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/43.jpg)
ICOS DEFICIENCYICOS DEFICIENCY
2% of patients with CVID
Autosomal recessive trait
Serum IgG and IgA levels were markedly
reduced in all patients
IgG<1.9-2.55 g/L
IgA<0.06-0.58g/L
Serum IgMlevel
reduced in 6/9 patients
low normal values in 3/9 patients
C.Bacchellietal.ClinicalandExperimentalImmunology2007, 149:401–409.Yongetal.ImmunologicalReviews2009;229:101–113.Park MA et al. Lancet
2008;372:489-502
![Page 44: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/44.jpg)
![Page 45: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/45.jpg)
![Page 46: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/46.jpg)
TACI MUTATION 10-20% of CVID patients Associated with
Lymphoproliferation splenomegaly Tonsillar hyperplasia follicular nodular hyperplasia of GI
Autoimmunity hemolytic anaemia Autoimmune thrombocytopaenia thyroiditis
TACI MutationTACI MutationPark MA et al. Lancet 2008;372:489-502.Young PFK et al. ImmunolAllergy ClinN Am 2008;28:367-86.C.Bacchellietal.ClinicalandExperimentalImmunology2007;149:401–409.
![Page 47: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/47.jpg)
BAFF-R DEFICIENCY
Described in only 1 patient 60-year-old male with
hypogammaglobulinaemia Profound reduction of both class switch
(CD27+, IgM-, IgD-) and non-switched memory (CD27+, IgM+, IgD+) Transitional B cell (CD38+++, IgM++) Plasmablasts(CD38+++, IgM-)
Park MA et al. Lancet 2008;372:489-502.
C.Bacchellietal.ClinicalandExperimentalImmunology2007;149:401–409.
![Page 48: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/48.jpg)
MUTS5(MSH5)
A gene encoded in MHC classIII region
A critical role in regulating meiotic
homologous recombination
A role in class switch recombination
Msh5 Mutation: associated with CVID
and selective IgA deficiency
![Page 49: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/49.jpg)
![Page 50: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/50.jpg)
![Page 51: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/51.jpg)
![Page 52: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/52.jpg)
MANAGEMENT
![Page 53: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/53.jpg)
IMMUNE GLOBULIN IgG replacement therapy started early,
cycle of recurrent infections leading to progressive lung damage can be mitigated.
Non-infectious complications of CVID,
such as autoimmune cytopenias prevented or treated by immune globulin therapy
![Page 54: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/54.jpg)
IMMUNE GLOBULIN Ig should not be given until evaluation
of patient's immune system including specific antibody responses.
Plans should be made to discontinue infusions for at least 4 mo, in order to reassess patient’s current immune status.
![Page 55: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/55.jpg)
![Page 56: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/56.jpg)
![Page 57: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/57.jpg)
EVALUATION OF ILLNESSES Children generally have higher rate of
viral infection than adults, due to increased exposure and other factors
CVID and fever should be evaluated promptly. identify organisms such as rapid viral identification kits for influenza or RSV.
Choice of ATB on culture data and test results and using narrow-spectrum drugs, avoid bacterial resistance.
![Page 58: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/58.jpg)
MONITORING PULMONARY STATUS Monitoring child for progressive but
subclinical pulmonary damage is important since pts can develop chronic pulmonary disease.
HRCT of chest may be of value in detecting early and progressive pulmonary structural damage
Repeat exams for decision such as administration of ATB or immune suppressants or increase in dose of Ig.
![Page 59: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/59.jpg)
VACCINATION Live viral vaccines contraindicated in CVID.
Killed viral and bacterial vaccines: hope that generate T cell-mediated immune responses that may afford some additional protection beyond that obtained with Ig replacement therapy.
Many children will retain ability to mount responses to some polysaccharide Ag, while they are non-responsive to others.
Immunization against transmissible infectious agents is encouraged for close family members.
Passive protection with hyperimmune globulin preparations, such as tetanus and varicella, is usually not necessary in patients already receiving standard Ig replacement therapy.
![Page 60: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/60.jpg)
PROGNOSIS Life span of children with CVID has been
significantly lengthened since Ig replacement therapy became standard of care
Prognosis is good.
Death during childhood from complications of CVID is extremely rare once immune globulin therapy is instituted.
Those children diagnosed after irreversible pulmonary disease has developed may have shorter life span
![Page 61: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/61.jpg)
![Page 62: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/62.jpg)
![Page 63: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/63.jpg)
![Page 64: Common variable immunodeficiency](https://reader036.vdocuments.us/reader036/viewer/2022062418/5560e1a9d8b42aa65e8b4c8c/html5/thumbnails/64.jpg)
Thank you